36P - Clinical impact and carcinogenic mechanism of USP3 overexpression in gastric cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Gastric Cancer
Translational Research
Presenter Kai-Yuan Lin
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors K. Lin
  • Department Of Medical Research, Chi Mei Medical Center, 710 - Tainan/TW



Gastric cancer (GC) is one of the most common malignancies in the world, yet little is known about the molecular process of its development and progression. In this study, we investigated the involvement of ubiquitin-specific protease 3 (USP3) in tumor progression, and in the prognosis of human GC.


The patient cohort in this study consisted of 147 GC cases from 1998 to 2005, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and real-time PCR were employed to examine the USP3 expression in 147 pairs of normal and GC tissues and 8 gastric cells. Based on the expression of USP3, one GC cell with high USP3 level was chosen for knockdown of USP3 expression. The effect of USP3 knockdown on the growth and spread of USP3-manupulated GC cells was examined.


USP3 protein overexpression was observed in 67 patients and was significantly correlated with Lauren classification, depth of invasion, nodal status, distant metastasis, staging, degree of differentiation, vascular invasion, and poor disease-free survival. Multivariate Cox regression analysis showed that USP3 overexpression is an independent prognostic marker for GC. Furthermore, USP3 expression was elevated in several GC cells. In vitro experiments indicated that USP3 knockdown inhibited GC cell growth and spread.


This study suggests that overexpression of USP3 can be a useful marker for predicting the outcome of GC patients and that USP3 targeting can represent a potential modality for treating GC.

Clinical trial indentification

Legal entity responsible for the study



Ministry of Science and Technology, Taiwan


All authors have declared no conflicts of interest.